Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Gynecologic 5Genitourinary 4Breast 3Tumor-Agnostic 2Thoracic 2Sarcoma 2NET 2Head & Neck 2Endocrine 2CNS 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasms, Unknown Primary 1Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
FAPI-46 × Tumor-Agnostic × Clear all
NCT06922825 2026-01-21

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT05263700 2023-03-31

FAPI-CUP

Peter MacCallum Cancer Centre, Australia

Phase NA Unknown
150 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡